Gemeinschaftspraxis für Hämatologie und Onkologie
- Address
- lock Available on a paid plan
Neoplasms Research
At Gemeinschaftspraxis für Hämatologie und Onkologie in Erfurt, clinical research is centered on neoplasms, with studies focused on improving care for patients living with cancer and related blood disorders.
- Breast cancer research exploring whether a targeted adjuvant treatment can improve disease-free survival and strengthen long-term outcomes.
- Polycythemia vera studies assessing treatment resistance and intolerance to help identify patients who may need alternative management strategies.
These trials reflect a practical mix of oncology and hematology research, aiming to refine treatment effectiveness and support more personalized care.
Hematology and Oncology Studies
The site’s trial portfolio brings together hematology and oncology research, with a strong emphasis on understanding how patients respond to treatment in real-world clinical practice.
- Polycythemia vera investigation of hydroxyurea resistance and intolerance using predictive risk factors to better guide therapy decisions.
- Breast cancer evaluation of a new adjuvant treatment approach for patients with high-risk, HER2-negative disease.
Overall, the research at this community practice is aimed at improving treatment selection, supporting clinical decision-making, and advancing care for patients with cancer and myeloproliferative disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gemeinschaftspraxis für Hämatologie und Onkologie
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Olaparib as Adjuvant Therapy in Germline BRCA1/2 Mutated High-Risk HER2-Negative Primary Breast Cancer: A Phase III Randomized Study | AstraZeneca AB | Phase III | Not Recruiting | Aug 2014 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Hydroxycarbamide | 1 | Unknown | 2023-07-28 | 2023-07-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.